3/1/2022,"Terms include $2 billion in cash up front, plus up to $335 million in additional cash payments to be paid in 2024, and $1 billion in convertible preferred equity that will give Viatris a 12.9% stake in Biocon Biologics.",Business/Barrons.comâ€¢43 minutes ago,Viatris to Sell Biosimilars Business for $3 Billion. Shares Tumble.,https://finance.yahoo.com/m/0c079f1e-d017-3cbe-8496-06a81368c845/viatris-to-sell-biosimilars.html
